Table 4.
Five-year cumulative budget impact results for the entire cohort (reference scenario versus scenarios 1–5)
| Difference | ||||||
|---|---|---|---|---|---|---|
| Reference scenario (£) | Scenario 1 (£) | Scenario 2 (£) | Scenario 3 (£) | Scenario 4 (£) | Scenario 5 (£) | |
| Access costs | 67,573,647 | 64,236 (0.10%) | 64,236 (0.10%) | -772,145 (-1.14%) | -1,533,465 (-2.27%) | 2,162,385 (3.20%) |
| Treatment costs | 2,818,006,173 | 15,825,109 (0.56%) | 55,320,485 (1.96%) | 34,513,656 (1.22%) | 15,651,634 (0.56%) | 56,467,306 (2.00%) |
| ESA costs | 173,328,756 | 755,080 (0.44%) | 755,080 (0.44%) | -3,477,002 (-2.01%) | -7,316,930 (-4.22%) | 10,903,915 (6.29%) |
| Monitoring costs | 49,553,898 | 191,026 (0.39%) | 191,026 (0.39%) | 303,374 (0.61%) | 405,098 (0.82%) | -288,277 (-0.58%) |
| Complication costs | 147,756,210 | 582,276 (0.39%) | 582,276 (0.39%) | 312,811 (0.21%) | 48,730 (0.03%) | 1,490,818 (1.01%) |
| Transportation costs | 620,677,229 | -36,982,815 (-5.96%) | -36,982,815 (-5.96%) | -70,900,727 (-11.42%) | -101,706,432 (-16.39%) | 101,841,215 (16.41%) |
| Total costs | 3,876,895,913 | -19,565,088 (-0.50%) | 19,930,289 (0.51%) | -40,020,032 (-1.03%) | -94,451,365 (-2.44%) | 172,577,361 (4.45%) |
Abbreviations: ESA Erythropoiesis-stimulating agents.